Fighting Childhood Obesity to Stay Healthy all Over the Life (OBELISK)

欧洲青少年晚期肥胖率从1980年的6%上升到32%，对严重肥胖、糖尿病和心血管疾病、过早死亡和残疾的流行产生了长期影响。有效地对抗成人肥胖是困难的，但事实证明，预防和治疗肥胖在年轻时效果更好。OBELISK的目标是消除欧洲肥胖流行的根源，首先以儿童为目标。OBELISK专注于肥胖的解释、预测、预防，为肥胖儿童带来精准医疗。OBELISK医学也是参与式的（4P），通过与家庭、科学和医学界、日托、学校、市政当局和行业的接触，利用社会创新的潜力来取得成功。OBELISK的目标是：1/在致病因素相互作用驱动（或预防）儿童时期从正常体重向肥胖过渡的分子机制方面取得突破，并开发和利用预防和治疗早期预测专有工具；2/确定至少3个新的儿童肥胖基因，并有望确定其他药物靶点；展示预防儿童肥胖的针对性方法的效用；4/在儿童肥胖治疗方面取得突破，包括对一种有前景的现有药物（GLP1R激动剂）进行现实临床研究，以逆转易患早期严重肥胖的突变人群的肥胖；5/利用项目成果，传播预防和治疗儿童肥胖的最佳做法，实施教育项目，并将OBELISK临床结果转化为政策制定者改变肥胖护理的指南和建议；促进与其他行动和项目建立联系和交流，以优化知识和联合活动。OBELISK定向方法应有助于将肥胖儿童变为肥胖成人的人数减少35%。

Obesity rates in late teens have increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetes and cardiovascular disease, premature death and disability. Efficiently fighting adult obesity is difficult but prevention and treatment of obesity have proven to work better at young ages. OBELISK goal is to cut the roots of the pandemic of obesity in Europe targeting children first. OBELISK is focused on elucidating, Predicting, Preventing obesity and bringing Precision medicine for children with obesity. OBELISK medicine is also Participative (4P), leveraging the potential of social innovation through engagement with families, scientific and medical communities, daycare, schools, municipalities, industries to achieve success. OBELISK objectives are: 1/ to bring breakthroughs in the molecular mechanisms by which causative factors interact to drive (or prevent) the transition from normal weight to obesity during childhood and to develop and exploit for prevention and treatment early predictive proprietary tools; 2/ to identify at least 3 novel childhood obesity genes with the prospect of identifying additional drug targets; 3/ to demonstrate the utility of targeted approaches to prevent childhood obesity; 4/ to bring breakthroughs in childhood obesity treatment including a real-life clinical study of a promising existing drug (GLP1R agonist) to reverse obesity in people with mutations predisposing to early severe obesity; 5/ to exploit the project results and disseminate best practices to prevent and treat childhood obesity, implementing education programs and translating OBELISK clinical results into guidelines and proposals for policy makers to change obesity care; 6/ to facilitate networking and exchanges with other actions and projects in order to optimize knowledge and joint activities. OBELISK targeted approach should contribute to decrease by 35% the number of children with obesity becoming adults with obesity.